The grades of 19 Biotechnology stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.

Vertex Pharmaceuticals Incorporated (VRTX) is seeing ratings go up from a C last week to a B this week. Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases. The company also gets A’s in sales growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of VRTX stock.

Celgene Corporation (CELG) improves from a C to a B rating this week. Celgene Corporation is a global integrated biopharmaceutical company engaged in the discovery, development, and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. The company also gets A’s in return on equity. For more information, get Portfolio Grader’s complete analysis of CELG stock.

BioMarin Pharmaceutical Inc. (BMRN) gets a higher grade this week, advancing from a C last week to a B. BioMarin Pharmaceutical Inc. develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of BMRN stock.

Eagle Pharmaceuticals, Inc.’s (EGRX) ratings are looking better this week, moving up to a A from last week’s B. For more information, get Portfolio Grader’s complete analysis of EGRX stock.

The rating of Loxo Oncology Inc (LOXO) moves up this week, rising from a B to a A. For more information, get Portfolio Grader’s complete analysis of LOXO stock.

This week, Adamas Pharmaceuticals, Inc. (ADMS) pushes up from a C to a B rating. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of ADMS stock.

Insys Therapeutics, Inc. (INSY) earns a A this week, jumping up from last week’s grade of B. Insys Therapeutics, Inc. develops pharmaceutical products that target the unmet needs of cancer patients, with a focus on cancer-supportive care. The company also gets A’s in sales growth, earnings growth, earnings revisions, earnings surprise, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of INSY stock.

This week, Applied Genetic Technologies Corp.’s (AGTC) ratings are up from a C last week to a B. The company also gets A’s in sales growth and earnings surprise. For more information, get Portfolio Grader’s complete analysis of AGTC stock.

Concert Pharmaceuticals, Inc. (CNCE) boosts its rating from a B to a A this week. The company also gets A’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of CNCE stock.

This is a strong week for Insmed Incorporated (INSM). The company’s rating climbs to B from the previous week’s C. Insmed Incorporated develops and commercializes drugs that treat metabolic diseases, endocrine disorders and oncology. For more information, get Portfolio Grader’s complete analysis of INSM stock.

uniQure N.V. (QURE) shows solid improvement this week. The company’s rating rises from a C to a B. The company also gets A’s in sales growth and earnings surprise. For more information, get Portfolio Grader’s complete analysis of QURE stock.

The rating of Enzymotec Ltd. (ENZY) moves up this week, rising from a B to a A. The company also gets A’s in sales growth, earnings revisions, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of ENZY stock.

This week, Chemocentryx, Inc.’s (CCXI) ratings are up from a C last week to a B. Chemocentryx, Inc. a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. For more information, get Portfolio Grader’s complete analysis of CCXI stock.

Tonix Pharmaceuticals Holding Corp. (TNXP) shows solid improvement this week. The company’s rating rises from a C to a B. For more information, get Portfolio Grader’s complete analysis of TNXP stock.

Medgenics, Inc. (MDGN) boosts its rating from a C to a B this week. Medgenics, Inc. is a biopharmaceutical company that develops therapeutic protein delivery technology for the treatment of a range of chronic diseases. The company also gets A’s in earnings surprise. For more information, get Portfolio Grader’s complete analysis of MDGN stock.

This week, Abeona Therapeutics, Inc. (ABEO) pushes up from a C to a B rating. The company also gets A’s in earnings surprise. For more information, get Portfolio Grader’s complete analysis of ABEO stock.

This is a strong week for PharmAthene, Inc. (PIP). The company’s rating climbs to B from the previous week’s C. PharmAthene, Inc. develops biological and chemical defense products. For more information, get Portfolio Grader’s complete analysis of PIP stock.

Biocept, Inc. (BIOC) gets a higher grade this week, advancing from a C last week to a B. Biocept, Inc. is a global provider of clinical trials services, providing medical image management and eClinical services, including electronic data capture and clinical data management solutions. The company also gets A’s in sales growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of BIOC stock.

Galena Biopharma, Inc. (GALE) earns a B this week, jumping up from last week’s grade of C. Galena Biopharma, Inc. is a biopharmaceuticals company that develops late-stage oncology drugs. The company also gets A’s in earnings revisions and earnings surprise. For more information, get Portfolio Grader’s complete analysis of GALE stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.